Author

Katja Schuster

Observed names: K Schuster, K. Schuster

Institution: The University of Texas Southwestern Medical Center

Observed institutions: University of Stuttgart, St. Jude Children's Research Hospital, The University of Texas MD Anderson Cancer Center, Arog Pharmaceuticals (United States), Dallas VA Medical Center, Harold C. Simmons Comprehensive Cancer Center, Martin Luther University Halle-Wittenberg, The University of Texas Southwestern Medical Center

OpenAlex ID: A5013293692

Aldehyde Dehydrogenase Activity Selects for Lung Adenocarcinoma Stem Cells Dependent on Notch Signaling

2010 · James P. Sullivan, Monica Spinola, et al. · Cancer Research · 416

Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring K-RAS Mutations

2009 · Georgia Konstantinidou, Erik A. Bey, et al. · Cancer Research · 142

Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib

2009 · Disha Dumka, Poonam Puri, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 49

Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis

2014 · Katja Schuster, Niranjan Venkateswaran, et al. · Molecular Cancer Research · 43

MDM2-A, a common Mdm2 splice variant, causes perinatal lethality, reduced longevity and enhanced senescence

2008 · Erin L. Volk, Katja Schuster, et al. · Disease Models & Mechanisms · 20

MDM2 Splice Variants Predominantly Localize to the Nucleoplasm Mediated by a COOH-Terminal Nuclear Localization Signal

2007 · Katja Schuster, Liying Fan, et al. · Molecular Cancer Research · 20

Reduced expression of hMSH2 protein is correlated to poor survival for soft tissue sarcoma patients

2003 · Helge W. Taubert, Frank Bartel, et al. · Cancer · 19

The MDM2-A Splice Variant of MDM2 Alters Transformation In vitro and the Tumor Spectrum in Both Arf- and p53-Null Models of Tumorigenesis

2009 · Erin L. Volk, Liying Fan, et al. · Molecular Cancer Research · 17

Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo

2011 · K Schuster, J Zheng, et al. · Blood Cancer Journal · 16

Loss of Heterozygosity at 12q14-15 Often Occurs in Stage I Soft Tissue Sarcomas and Is Associated with MDM2 Amplification in Tumors at Various Stages

2003 · Helge Taubert, Katja Schuster, et al. · Modern Pathology · 13

A novel L ‐neopentylglycine derivative as auxiliary for copper‐catalyzed asymmetric Michael reactions

2003 · Jens Christoffers, Katja Schuster · Chirality · 12

Differential cooperation of oncogenes with p53 and Bax to induce apoptosis in rhabdomyosarcoma

2006 · Alan C Taylor, Katja Schuster, et al. · Molecular Cancer · 8

Comparative evaluation of microsatellite marker, AP-PCR and CGH studies in primary renal cell carcinoma

2004 · Christian Hoefling, Hannelore Schmidt, et al. · International Journal of Molecular Medicine · 7

Selection for mutations in the cDNAs of transgenic mice upon expression of an embryonic lethal protein

2007 · Katja Schuster, Linda C. Harris · Transgenic Research · 6

Gain-of-Function KIT Mutations Sensitize the Mutant Isoform to the Type I Tyrosine Kinase Inhibitor Crenolanib: A Rationale for the Therapeutic Use in Systemic Mastocytosis (SM) and Core Binding Factor Leukemias (CBFL)

2014 · Marcus M Schittenhelm, Figen Akmut, et al. · Blood · 4

Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib

2009 · Disha Dumka, Poonam Puri, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4

Loss of heterozygosity at 12q14–15 often occurs in stage I soft tissue sarcomas and is associated with MDM2 amplification in tumors at various stages

2004 · H. Taubert, K. Schuster, et al. · Pathology - Research and Practice · 2

The SUMO Ligase PIAS1 Promotes the Progression and Survival of Solid Tumors of Different Histopathological Origins

2013 · Jerfiz D Constanzo, Andrea Rabellino, et al. · The FASEB Journal · 1

Supplementary Figure 6 from Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis

2023 · Katja Schuster, Niranjan Venkateswaran, et al.

Supplementary Methods, Figure Legends from Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis

2023 · Katja Schuster, Niranjan Venkateswaran, et al.

Supplementary Table 1 from Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis

2023 · Katja Schuster, Niranjan Venkateswaran, et al.

Supplementary Figure 5 from Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis

2023 · Katja Schuster, Niranjan Venkateswaran, et al.

Supplementary Figure 4 from Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis

2023 · Katja Schuster, Niranjan Venkateswaran, et al.

Supplementary Figure 3 from Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis

2023 · Katja Schuster, Niranjan Venkateswaran, et al.

Supplementary Figure 1 from Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis

2023 · Katja Schuster, Niranjan Venkateswaran, et al.

Works count: 85

Citation count: 799

H-index: 11

I10-index: 11